SCHEMBL262202

SCHEMBL262202

O=C(O)c1cn(C2CCCC2)c2cc(F)ccc2c1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.67
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 5/20 0.52
LMNA P02545 3/20 0.52
TOP2A P11388 3/20 0.52
TOP2B Q02880 3/20 0.52
HPGD P15428 3/20 0.52
HSD17B10 Q99714 3/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 1/20 0.52
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.45
PIK3CG P48736 3/20 0.45
PIK3CD O00329 2/20 0.45
PIK3R1 P27986 2/20 0.45
PIK3CA P42336 2/20 0.45
GAA P10253 1/20 0.44
DPP4 P27487 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9146620 0.95 KDM4E (0.59) KDM4EALDH1A1LMNATOP2ATOP2B
SCHEMBL27977216 0.86 KDM4E (0.68) KDM4EMEN1KMT2AALDH1A1LMNA
SCHEMBL7127052 0.85 KDM4E (0.67) KDM4EMEN1KMT2AALDH1A1LMNA
SCHEMBL1243805 0.84 KDM4E (0.63) KDM4EMEN1KMT2AALDH1A1LMNA
SCHEMBL2744582 0.84 KDM4E (0.59) KDM4EALDH1A1LMNATOP2ATOP2B
SCHEMBL29766836 0.84 KDM4E (0.59) KDM4EALDH1A1LMNATOP2ATOP2B
SCHEMBL7121601 0.84 KDM4E (0.69) KDM4EMEN1KMT2AALDH1A1LMNA
SCHEMBL10757644 0.84 KDM4E (0.47) KDM4EMEN1KMT2AALDH1A1LMNA
SCHEMBL28458144 0.83 KDM4E (0.57) KDM4EALDH1A1LMNATOP2ATOP2B
Hydrochloric Acid SCHEMBL6004997 0.83 KDM4E (0.57) KDM4EALDH1A1LMNATOP2ATOP2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103965163-B A kind of carbostyril derivative containing pyrimidine ring and its production and use FUDAN UNIVERSITY (CN) 2016-01-20 CN disclosed
CN-103965163-A Pyrimidine ring-containing quinolone derivatives as well as preparation method and application thereof UNIV FUDAN 2014-08-06 CN disclosed
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
CN-101400655-A Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2009-04-01 CN disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 KDM4E 3062/4885MEN1 3327/4885KMT2A 2966/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 KDM4E 3128/4885MEN1 2994/4885KMT2A 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.